

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/014097 A1

(51) International Patent Classification⁷: **C07D 295/02**,
A61K 31/495, A61P 25/24

(21) International Application Number: PCT/EP02/08696

(22) International Filing Date: 5 August 2002 (05.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/311,504 10 August 2001 (10.08.2001) US
60/384,711 31 May 2002 (31.05.2002) US

(71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH];
Grenzacherstrasse 124, CH-4070 Basle (CH).

(72) Inventors: **BERGER, Jacob**; 12135 Dawn Lane, Los Al-
tos Hills, CA 94022 (US). **CLARK, Robin, Douglas**; 2025
Columbia Street, Palo Alto, CA 94306 (US). **ZHAO, Shu,**
Hai; 426 Ositos Avenue, Sunnyvale, CA 94086 (US).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124,
CH-4070 Basle (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ARYLSULFONYL DERIVATIVES WITH 5-HT₆ RECEPTOR AFFINITY

(57) Abstract: This invention relates to compounds which have generally HT₆ receptor affinity and which are represented by formula (1), wherein Ar, R¹ and R² are as defined in the specification, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, their use as therapeutic agents, and methods of preparation thereof.



WO 03/014097 A1